Evelo Biosciences, Inc. 4 SEC Filings

Filed On	Filing
08 Nov 2023	Form 4: Bodmer Mark, CSO, President of R&D Received 6,625 shares by exercise or conversion · Sold 3,163 shares ($1.04K)
08 Nov 2023	Form 4: McHale Duncan, Chief Medical Officer Received 6,500 shares by exercise or conversion · Sold 3,103 shares ($1.02K)
08 Nov 2023	Form 4: Gill Simba, Director Received 1,172 shares by exercise or conversion · Sold 172 shares ($56.8)
08 Nov 2023	Form 4: Thorell Marella, Chief Financial Officer Received 6,500 shares by exercise or conversion · Sold 1,811 shares ($598)
03 Nov 2023	Form 4: Bodmer Mark, CSO, President of R&D Received 12,500 shares by exercise or conversion · Sold 6,854 shares ($2.26K)
03 Nov 2023	Form 4: McHale Duncan, Chief Medical Officer Received 12,500 shares by exercise or conversion · Sold 6,854 shares ($2.26K)
03 Nov 2023	Form 4: Thorell Marella, Chief Financial Officer Received 12,500 shares by exercise or conversion · Sold 3,999 shares ($1.32K)
29 Sep 2023	Form 4: Gill Simba, Director Received 15,000 shares by exercise or conversion · Granted 60,000 Restricted Stock Units · Sold 1,996 shares ($7.86K)
13 Sep 2023	Form 4: Bodmer Mark, CSO, President of R&D Granted 37,500 Restricted Stock Units
13 Sep 2023	Form 4: Thorell Marella, Chief Financial Officer Granted 37,500 Restricted Stock Units
13 Sep 2023	Form 4: McHale Duncan, Chief Medical Officer Granted 37,500 Restricted Stock Units
09 Aug 2023	Form 4: Bodmer Mark, CSO, President of R&D Received 6,625 shares by exercise or conversion · Sold 3,128 shares ($29.7K)
09 Aug 2023	Form 4: Gill Simba, Director Received 1,171 shares by exercise or conversion · Sold 342 shares ($3.25K)
09 Aug 2023	Form 4: McHale Duncan, Chief Medical Officer Received 6,500 shares by exercise or conversion · Sold 3,434 shares ($32.7K)
09 Aug 2023	Form 4: Thorell Marella, Chief Financial Officer Received 6,500 shares by exercise or conversion · Sold 2,004 shares ($19.1K)
13 Jul 2023	Form 4: Flagship Ventures Fund Iv General Partner Llc, 10% owner and 7 others Bought 5,411,255 shares ($12.5M)
12 Jul 2023	Form 4: Reynolds Alexander C, Director Granted 2,000 Stock Option (Right to Buy)
12 Jul 2023	Form 4: Moore Jeffrey R., Director Granted 2,000 Stock Option (Right to Buy)
12 Jun 2023	Form 4: Williams Tonya, Director Granted 20,000 Stock Option (Right to Buy)
12 Jun 2023	Form 4: Gutierrez-Ramos Jose-Carlos, Director Granted 20,000 Stock Option (Right to Buy)

Comments